The first 266,000 flu vaccines manufactured by Sanofi have passed state quality control and are being distributed to pharmacies and medical facilities.
According to the Ministry of Health, three batches of the vaccine have received a positive assessment from the Ukrainian Agency for Medicines and Medical Devices.
In addition, a flu vaccine manufactured in South Korea is currently undergoing laboratory testing. It is planned that 140,000 doses of this vaccine will enter the Ukrainian market in the near future, following approval by state authorities.
As previously reported, 406,000 doses of flu vaccine were expected to be delivered during the current flu season; deliveries are scheduled for November—140,000 doses of GC Flu vaccine manufactured by GC Biopharma Corp. (South Korea), imported by Biolabs LLC, and 266,000 doses of the Vaxigrip vaccine manufactured by Sanofi-Inotrop Industries (France), imported by Sanofi-Aventis Ukraine LLC.
During the 2025–2026 flu season, 136,000 doses of the GC Flu vaccine and 100,670 doses of Vaxigrip Tetra passed state quality control.
A year earlier, during the 2024–2025 flu season, approximately 370,000 doses of flu vaccines were delivered to Ukraine (250,000 doses of Vaxigrip Tetra and 120,000 doses of GC Flu). According to a representative of the GC Flu importer, approximately one-third of the Korean vaccine had to be disposed of due to low demand.
The Cabinet of Ministers has supported the submission to the Verkhovna Rada of a draft law on state regulation of genetic engineering activities and control over the circulation of products containing genetically modified organisms (GMO), this initiative is conducting a comprehensive review of the existing legislation in the field of handling GMO products, and also allows implementing EU regulations in force in the Ukrainian legislation.
The government made the corresponding decision without discussion at a meeting on August 4.
“Imperfect legal regulation of GMO handling makes it impossible to effectively control the circulation of GMO products and creates conditions for the illegal use of unregistered GMO products. Thus, state regulation in the field of GMO handling should be revised, modernized and brought in line with EU legislation,” an explanatory note to the document reads.
This bill provides for the delineation of powers of the authorities to eliminate duplication of functions in the field of GMO circulation, improvement of the system for assessing the risks of the impact of GMOs on human health and the environment, the introduction of European mechanisms for state registration and labeling of products with GMOs, strengthening state control in the sphere of handling GMOs.
The bill introduces a new type of permits – “permits for the import of unregistered GMOs for carrying out genetic engineering activities in a closed system” with a gradation of the levels of risks they create from 1 to 4.
It is assumed that this bill will regulate the creation, labeling and use of GMOs and genetically modified products, control of compliance with legislation in this industry. In addition, the document prohibits the circulation of food products containing GMOs (or produced with their use) prior to the state registration of the corresponding source of origin of GMOs.
